Efficacy and Safety of Cefditoren Pivoxil Versus Ciprofloxacin in Acute Uncomplicated Cystitis

PHASE3CompletedINTERVENTIONAL
Enrollment

611

Participants

Timeline

Start Date

November 30, 2007

Primary Completion Date

December 31, 2009

Study Completion Date

June 30, 2010

Conditions
Urinary Tract Infections
Interventions
DRUG

cefditoren pivoxil

400 mg, oral, single dose during 3 days

DRUG

Ciprofloxacin

250 mg, oral, twice a day for 3 days

Trial Locations (30)

11408

CS San Telmo, Jerez de la Frontera

14900

CS Lucena, Lucena

14940

CS Cabra, Cabra

14960

CS Rute, Rute

20150

CS Billabona, Billabona

20230

CS Legazpi, Legazpi

22400

CS Monzón Urbano, Monzón

48013

CS Basurto, Bilbao

50006

CS Sagasta Ruiseñores, Zaragoza

50007

CS Torrero La Paz, Zaragoza

50013

CS Torre Ramona, Zaragoza

50015

CS Arrabal, Zaragoza

50017

CS Bombarda, Zaragoza

Unknown

General Hospital of Chest Disease of Athens, Athens

General Hospital of Thessaloniki, Thessaloniki

03500

CS Rincón de Loix, Benidorm

08940

CAP Cornella, Cornellà de Llobregat

08820

CAP 17 setembre, el Prat de Llobregat

08850

CAP Bartomeu Fabres Anglada, Gavà

08902

CAP Amadeu Torner, L'Hospitalet de Llobregat

08905

CAP Florida Nord, L'Hospitalet de Llobregat

08430

CAP Dr. Vicens Papaceit, La Roca del Vallès

08243

CAP Les Bases-Manresa 3, Manresa

08302

CAP La Riera, Mataró

08303

CAP El Maresme, Mataró

08670

CAP Navas-Balsareny, Navàs

08500

CAP Remei, Vic

03540

CS Cabo Huertas, Alicante

08018

CAP El Clot, Barcelona

08025

Fundacion Puigvert, Barcelona

All Listed Sponsors
lead

Tedec-Meiji Farma, S.A.

INDUSTRY

NCT00598403 - Efficacy and Safety of Cefditoren Pivoxil Versus Ciprofloxacin in Acute Uncomplicated Cystitis | Biotech Hunter | Biotech Hunter